Skip to main content

Table 1 Baseline characteristics of RA patients included in the discovery study

From: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment

Characteristic Good-responders (n = 50) Non-responders (n = 20) p value
Age, mean (SD) 58.1 (13.1) 55.3 (13) 0.42a
Female, n (%) 31 (62) 15 (75) 0.30b
Days on drug at outcome, median (IQR) 113 (92, 147) 109 (93, 147) 0.74c
Baseline DAS28, mean (SD) 5.07 (0.90) 5.09 (0.90) 0.93a
Concurrent DMARD therapy, n (%) 46 (92) 15 (75) 0.06b
Swollen joint count, median (IQR) 8 (5, 11) 6 (3, 8) 0.13c
Tender joint count, median (IQR) 12 (6, 17) 17 (9, 23) 0.15c
Baseline HAQ score, median (IQR) 1.5 (1, 2.13) 1.8 (1.4, 2.3) 0.21c
  1. Patients were stratified by EULAR response at 3 months. All patients receiving concurrent DMARD therapy were receiving methotrexate. DAS28 28-joint count disease activity score, DMARD disease modifying anti-rheumatic drugs, HAQ health assessment questionnaire, SD standard deviation, IQR interquartile range. p value: atwo-sample t test, bchi-squared test, cWilcoxon rank-sum test